Advertisement

European Journal of Pediatrics

, Volume 144, Issue 2, pp 160–163 | Cite as

Hepatitis B vaccination and immune response in children with malignant diseases

  • U. Entacher
  • O. Jürgenssen
  • L. Thun-Hohenstein
  • G. Simbruner
  • A. Khoss
  • H. Wank
  • G. Neuwirth
  • H. Gadner
  • W. Frisch-Niggemeyer
Original Investigations

Abstract

Fifty children with malignant diseases were vaccinated against hepatitis B. Twenty-nine children suffered from leukaemia or non-Hodgkin's lymphoma; 14 of these were on intensive chemotherapy (group I) and 15 were without intensive therapy (group II). The other 21 children had various forms of solid tumours, 14 of them were on intensive therapy (group III) and 7 were without intensive therapy (group IV). To evaluate the immune response, we determined antibody titres over a period of more than 14 weeks after the first vaccination. As 22 out of 50 patients had received passive immunisation together with either the first or the first and second vaccination, antibody titres at the 14th and 18th week (i.e. more than 10 weeks after passive immunisation) were used to evaluate the vaccination results. An antibody titre of ≥10 mIU/ml was considered to be a positive response. All patients of group IV, but only 4 out of 14 in group III, 4 out of 15 in group II, and 0 out of 14 in group I produced antibody titres higher than 50 mIU/ml. In contrast to the full response in group IV, two-thirds of all other patients had no immune response (<10 mIU/ml). Based on our experience we recommend vaccinating patients suffering from solid tumours and receiving no intensive therapy (group IV) against hepatitis B and protecting all the other children with malignant diseases by passive immunisation, if necessary.

Key words

Hepatitis B: prevention and control Vaccination Paediatrics Medical oncology 

Abbreviations

ALL

acute lymphatic leukaemia

AML

acute myelocytic leukaemia

CML

chronic myelocytic leukaemia

NHL

non-Hodgkin's lymphoma

RMS

rhabdomyosarcoma

HBV

hepatitis B virus

HBsAg

hepatitis B surface antigen

HBeAg

hepatitis B “e” antigen

anti-HBs

antibody against HBsAg

RIA

radioimmunoassay

BFM 81 protocol

ALL therapy protocol 1981 (“Berlin-Frankfurt-Münster”)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baraldini M, Miglio F, Pirillo L, Cursaro C, Meliconi R, Stefanini GF, Gasbarrini G (1983) Hepatitis B virus markers in hematologic patients: relation to transfusion treatment and hospitalization. Vox Sang 45:112–120Google Scholar
  2. 2.
    Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, Lacour B, Prunet P, Cerisier Y, Guesry P (1981) Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II. Haemodialysis patients. Lancet I:797–800Google Scholar
  3. 3.
    Deinhardt F (1983) Suggested immunization programs with hepatitis B vaccine for high-risk groups. In: Papaevangelou G, Hennessen W (eds) Developments in biological standardization 54: Viral hepatitis: Standardization in immunoprophylaxis of infections by hepatitis viruses. S Karger, Basel Munich Paris London New York Sydney, pp 307–309Google Scholar
  4. 4.
    Goldblum SE, Reed WP (1980) Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 93:597–613Google Scholar
  5. 5.
    Goudeau A, Dubois F, Barin F, Dubois MC, Coursaget P (1983) Hepatitis B vaccine: clinical trials in high-risk settings in France. In: Papaevangelou G, Hennessen W (eds) Developments in biological standardardization 54: Viral hepatitis: Standardization in immunoprophylaxis of infections by hepatitis viruses. S Karger, Basel Munich Paris London New York Sydney, pp 267–284Google Scholar
  6. 6.
    Goudeau A, Dubois F, Geslin N, Pierre D (1983) Hepatitis B vaccine: simultaneous passive and active immunization. Indications in pre- and post-exposure. In: Papaevangelou G, Hennessen W (eds) Developments in biological standardization 54: Viral hepatitis: Standardization in immunoprophylaxis of infections by hepatitis: viruses. S Karger, Basel Munich Paris London New York Sydney, pp 259–265Google Scholar
  7. 7.
    Henze G, Langermann HJ, Fengler R, Brandeis M, Evers KG, Gadner H, Hinderfeld L, Jobke A, Kornhuber B, Lampert F, Lasson U, Ludwig R, Müller-Weihrich S, Neidhardt M, Nessler G, Niethammer D, Rister M, Ritter J, Schaaff A, Schellong G, Stollmann B, Treuner J, Wahlen W, Weinel P, Wehinger H, Riehm H (1982) Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: intensivierte Reinduktionstherapic für Patientengruppen mit unterschiedlichem Rezidivrisiko. Klin Pädiatr 194/4:195–203Google Scholar
  8. 8.
    Kunz Ch, Hofmann H, Frisch-Niggemeyer W (1984) Erfahrungen mit der Impfung gegen Hepatitis B. Wien Klin Wochenschr 96/4:158–161Google Scholar
  9. 9.
    Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M (1980) Hepatitis B vaccine: Immune responses in haemodialysis patients. Lancet II:1211–1213Google Scholar
  10. 10.
    Sung JL, Chen DS (1983) Hepatitis B surface antigen in saliva, urine and ascites. Hepatogastroenterology 30:183Google Scholar
  11. 11.
    Tabor E, Gerety RJ, Mott M, Wilbur J (1978) Prevalence of hepatitis B in a high-risk setting: a serologic study of patients and staff in a pediatric oncology unit. Pediatrics 61:711–715Google Scholar
  12. 12.
    Wands JR, Walker JA, Davis TT, Waterbury LA, Owens AH, Carpenter CCJ (1974) Hepatitis B in an oncology unit. NEJ Med 291:1371–1375Google Scholar
  13. 13.
    Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterol 68:105–112Google Scholar
  14. 14.
    Zoulek G, Deinhardt F (1983) Immunprophylaxe der Hepatitis B: 3. Ergebnisse klinischer Studien mit Hepatitis-B-Impfstoffen. Dtsch Med Wochenschr 108:1223–1229Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • U. Entacher
    • 1
  • O. Jürgenssen
    • 1
  • L. Thun-Hohenstein
    • 1
  • G. Simbruner
    • 1
  • A. Khoss
    • 1
  • H. Wank
    • 2
  • G. Neuwirth
    • 2
  • H. Gadner
    • 2
  • W. Frisch-Niggemeyer
    • 3
  1. 1.Department of PediatricsUniversity of ViennaViennaAustria
  2. 2.St. Anna Children's HospitalViennaAustria
  3. 3.Institute of VirologyUniversity of ViennaAustria

Personalised recommendations